Life Sciences and Healthcare

On the acquisition of a 70% stake in AnaPath Services, a Swiss contract laboratory services and histopathology company whilst simultaneously advising AnaPath Services on its 100% acquisition of Spanish contract research organisation, Envigo CRS involving the coordination of three jurisdictions.

On the USD 4.3bn acquisition of Sunrise Senior Living – Welltower’s entry into the UK market. We subsequently advised on the acquisitions of over USD 500m of care home assets and the GBP 226m sale and leaseback of four acute care hospitals.

On the sale of InstaDeep to BioNTech, at a value of approximately GBP362 million plus earn-out of up to approximately £200 million.

On all aspects relating to its entry to China, including corporate structuring, WFOE set-up, compliance, drug registration and importation, clinical trial requirements, data exclusivity and IP strategy and risk management and contractual documentation.

On regulatory advice to the UK biopharmaceutical company on the marketing of drugs containing psychotropic substances, covering issues including warehouse authorisations, reimbursement procedures and access to special marketing programmes for innovative drugs.

On the sale of Echo, a UK start-up whose app helps people manage their medication and order repeat prescriptions for delivery, to leading healthcare organisation McKesson, owner of LloydsPharmacy.

On a successful infringement litigation case regarding imitations of medical devices across multiple jurisdictions, including Austria, the Netherlands, Slovenia, Germany, Belgium, Croatia, Italy and France.

On defence against a threatened group litigation order by almost 30 claimants following a medical device alert concerning implantable devices.

On multinational product liability coordination involving crop protection products across six jurisdictions.

On representation before the European patent office in contested proceedings relating to CGPR monoclonal antibodies in pain treatments.

On their strategy of partnering with Chinese companies on commercialising and potential local manufacturing of their several products.

On healthcare advertising, competition law and regulatory advice covering several substantial matters.